Immuneering acquires BioArkive for $8.75M in stock; delays IMM-1-104 IND to Q3 2022

Immuneering Corp

Acquired BioArkive for $8.75M in stock (379,635 shares); BioArkive CRO to be fully integrated into Immuneering.
Assumed BioArkive's San Diego lease: 38,613 sq ft, monthly base rent ~$56K, term through April 2032.
IMM-1-104 IND submission delayed to Q3 2022; first patient enrollment now Q4 2022 due to supply chain constraints.
28 BioArkive employees become Immuneering employees; Brett Hall (Immuneering CSO) held majority of BioArkive shares.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.